Cullinan Net Interest Income from 2010 to 2026
| CGEM Stock | USD 12.23 0.38 3.21% |
Net Interest Income | First Reported 2019-12-31 | Previous Quarter 5.9 M | Current Value 5.1 M | Quarterly Volatility 3.1 M |
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 63.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.86, Dividend Yield of 0.0 or PTB Ratio of 1.05. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
Cullinan | Net Interest Income | Build AI portfolio with Cullinan Stock |
Evaluating Cullinan Oncology's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cullinan Oncology LLC's fundamental strength.
Latest Cullinan Oncology's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Cullinan Oncology LLC over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Cullinan Oncology's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cullinan Oncology's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Cullinan Net Interest Income Regression Statistics
| Arithmetic Mean | 7,845,850 | |
| Geometric Mean | 1,407,343 | |
| Coefficient Of Variation | 168.42 | |
| Mean Deviation | 10,567,888 | |
| Median | 397,000 | |
| Standard Deviation | 13,213,607 | |
| Sample Variance | 174.6T | |
| Range | 35.4M | |
| R-Value | 0.77 | |
| Mean Square Error | 74.4T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | 2,027,825 | |
| Total Sum of Squares | 2793.6T |
Cullinan Net Interest Income History
About Cullinan Oncology Financial Statements
Cullinan Oncology investors utilize fundamental indicators, such as Net Interest Income, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 34.1 M | 35.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Cullinan Oncology Correlation against competitors. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Biotechnology sector continue expanding? Could Cullinan diversify its offerings? Factors like these will boost the valuation of Cullinan Oncology. Projected growth potential of Cullinan fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cullinan Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Cullinan Oncology LLC using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cullinan Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cullinan Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between Cullinan Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cullinan Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cullinan Oncology's market price signifies the transaction level at which participants voluntarily complete trades.